We are a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Our goal is to transform the treatment paradigm for patients suffering from these potentially life-threatening conditions for which there are no approved medicines or where existing approved medicines have limitations.
Location: United States, New York, Uniondale
Employees: 51-200
Founded date: 1998
Investors 1
| Date | Name | Website |
| - | Formic Ven... | formic.vc |
Mentions in press and media 3
| Date | Title | Description |
| 05.01.2022 | Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference | -- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Angio... |
| 10.11.2019 | Angion’s kidney therapy advances | “There were two graft failures in the placebo arm and none in the drug arm,” said Angion President and CEO Jay Venkatesan in a phone interview. “But, in fact, there were twice as many patients in the drug arm. That the graft actually surviv... |
| - | Angion’s kidney therapy advances | Angion Biomedica announced positive phase II clinical trial results for its drug ANG-3777, which treats acute kidney injuries. The study tested whether the small molecule could help kidney transplant patients suffering from delayed graft fu... |